Abeona Therapeutics Inc (ABEO)
EBITDA Growth
-114.80%
Quarterly · Period ending:
ABEO EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-114.80%period ending
Latest reported-114.80%period ending
ABEO Quarterly EBITDA YoY % (-236.11% → -114.80%)
Year-over-year change
High-resolution chart · PNG
ABEO ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -114.8029% | |
| -50.4894% | |
| -151.432% | |
| 34.7196% | |
| 1,275.8594% | |
| 65.8351% | |
| 52.8139% | |
| -159.0619% | |
| 158.3148% | |
| -268.342% | |
| -43.582% | |
| -33.2201% | |
| -94.0356% | |
| 39.0083% | |
| 15.4965% | |
| -56.1872% | |
| 35.7709% | |
| 1.3855% | |
| 4.4853% | |
| -9.7774% | |
| -13.3303% | |
| -3.943% | |
| -0.8827% | |
| 68.6636% | |
| 49.1243% | |
| 23.152% | |
| 27.8937% | |
| 3.5887% | |
| -82.9874% | |
| -63.2087% | |
| -125.1716% | |
| -205.8043% | |
| -48.0977% | |
| -107.2673% | |
| -22.971% | |
| -116.7014% | |
| -23.7387% | |
| 6.9486% | |
| -208.5923% | |
| 59.4494% | |
| -63.8854% | |
| -185.3801% | |
| -377.7293% | |
| -348.221% | |
| 67.8309% | |
| -155.4839% | |
| 53.1218% | |
| -2,101.6667% | |
| -567.9909% | |
| -117.8485% | |
| 84.9669% | |
| 99.5908% | |
| 125.3842% | |
| 188.3487% | |
| -238.5419% | |
| -748.5532% | |
| -374.567% | |
| -123.6111% | |
| 357.8889% | |
| 22.7537% | |
| -16.6401% | |
| -31.9848% | |
| -12.0764% | |
| 42.271% | |
| 7.157% | |
| 16.4289% | |
| -32.9238% | |
| -3.1408% | |
| 3.0622% | |
| 81.9646% | |
| 33.7493% | |
| -136.2893% | |
| -36.1564% | |
| -1,683.1071% | |
| -215.9119% | |
| -475% | |
| -603.2787% | |
| 252.0642% | |
| 184.4397% | |
| 149.9411% | |
| 113.9269% | |
| 59.2904% | |
| 16.3854% | |
| 57.1861% | |
| -12.9448% | |
| 41.4434% | |
| -5.2828% | |
| -15.5594% | |
| -31.2796% | |
| 7.766% | |
| -10.657% | |
| 30.7506% | |
| 24.334% | |
| -20.109% | |
| -41.7155% | |
| -46.1947% | |
| -35.6498% | |
| -39.5604% | |
| 17.5333% | |
| -22.5597% |